News
HC Wainwright & Co. Maintains Buy on MiNK Therapeutics, Lowers Price Target to $9
21 Mar 24
News, Price Target, Analyst Ratings
MiNK Therapeutics Q4 EPS $(0.16) Misses $(0.15) Estimate
21 Mar 24
Earnings, News
Earnings Scheduled For March 21, 2024
21 Mar 24
Earnings
Earnings Outlook For MiNK Therapeutics
20 Mar 24
Earnings
MiNK Announces Preclinical Data Showcasing Activity Of MiNK-215 Against Colorectal Cancer Liver Metastases At AACR 2024
6 Mar 24
Biotech, News, General
MiNK Therapeutics, Inc. Announces First Refractory Gastric Cancer Patient Dosed In Phase 2 Trial With Novel Combination Of Co's Allogeneic INKT Cell Therapy And Agenus' Botensilimab And Balstilimab
14 Feb 24
Biotech, News, General
12 Health Care Stocks Moving In Wednesday's After-Market Session
7 Feb 24
Movers
MiNK Therapeutics' AgenT-797 Presents Results In The Treatment Of Severe Acute Respiratory Distress, Published In Nature Communications
6 Feb 24
Biotech, News, General
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
6 Feb 24
Movers
MiNK Therapeutics' MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
30 Jan 24
News